Skip to Content

Dofetilide Pregnancy and Breastfeeding Warnings

Dofetilide is also known as: Tikosyn

Medically reviewed on Apr 13, 2018

Dofetilide Pregnancy Warnings

Dofetilide has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of teratogenicity after doses greater than or equal to 2 mg/kg/day. There are no controlled data in human pregnancy. Dofetilide is only recommended for use during pregnancy when there are no alternatives and benefit outweighs risk.

See references

Dofetilide Breastfeeding Warnings

There are no data on the excretion of dofetilide into human milk. The manufacturer recommends against breast-feeding during therapy with dofetilide.

See references

References for pregnancy information

  1. Webster WS, Brown-Woodman PD, Snow MD, Danielsson BR "Teratogenic potential of almokalant, dofetilide, and d-sotalol: drugs with potassium channel blocking activity." Teratology 53 (1996): 168-75
  2. "Product Information. Tikosyn (dofetilide)" Pfizer US Pharmaceuticals, Atlanta, GA.

References for breastfeeding information

  1. "Product Information. Tikosyn (dofetilide)" Pfizer US Pharmaceuticals, Atlanta, GA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.